|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.1500 - 0.1500|
|52 Week Range||0.0001 - 0.1500|
|Beta (5Y Monthly)||-373.48|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Roumell Asset Management disclosed a large stake in molecular-diagnostics biotech Enzo Biochem and urged the company to accept the resignation of its CEO. Icahn Enterprises lowered its investment in auto-parts maker Tenneco.
DermTech, Inc. (NASDAQ: DMTK) ("DermTech"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its presentation at the 2021 Dermatology Summit virtual conference (the "Dermatology Summit") on Jan. 8, 2021. The Dermatology Summit uniquely brings together members of the financial community and business leaders from established and emerging companies in the dermatology space to help foster investment and partnerships in the next generation of dermatology companies and products.
DermTech, Inc. (NASDAQ: DMTK) ("DermTech"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that SKIN has published the results of a large registry study finding that the evaluation of genomic atypia using DermTech’s Pigmented Lesion Assay (the "PLA") may be a superior approach to guide treatment decisions and manage pigmented lesions, when compared to visual assessment of pigmented lesions.